Extranodal NK-T-cell lymphoma staging: Difference between revisions
No edit summary |
No edit summary |
||
(13 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{RG}} | {{CMG}}; {{AE}} {{RG}} | ||
==Overview== | ==Overview== | ||
Extranodal NK/T cell lymphoma survival rate is not well predicted by [[Ann Arbor staging system]]. A new system was introduced based on [[B symptoms]], [[Ann Arbor Staging|Ann Arbor system]], [[LDH]] level, and regional [[lymphadenopathy]] combined. Another parallel mechanism for extranodal NK/T cell lymphoma is based on [[tumor]] [[biologic]] and micro-environmental factors. High [[Ki-67 (Biology)|Ki-67]] [[nuclear]] antigen is a [[marker]] for actively proliferation [[tumor]] [[Cell (biology)|cell]] which could be a related factor with mass bulk. | |||
==Staging== | ==Staging== | ||
Extranodal NK/T cell lymphoma survival rate is not well predicted by [[Ann Arbor staging system]] | |||
* Extranodal NK/T cell lymphoma survival rate is not well predicted by [[Ann Arbor staging system]]<ref name="pmid12876666">{{cite journal| author=Jaffe ES, Krenacs L, Raffeld M| title=Classification of cytotoxic T-cell and natural killer cell lymphomas. | journal=Semin Hematol | year= 2003 | volume= 40 | issue= 3 | pages= 175-84 | pmid=12876666 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12876666 }} </ref>|<ref name="pmid16888893">{{cite journal| author=Feller AC| title=[Classification and differential diagnosis of NK/T-cell lymphomas]. | journal=Verh Dtsch Ges Pathol | year= 2003 | volume= 87 | issue= | pages= 43-52 | pmid=16888893 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16888893 }}</ref>. | |||
*A new system was introduced by a Korean study based on [[B symptoms]], [[Ann Arbor Staging|Ann Arbor system]], [[LDH]] level, and regional [[lymphadenopathy]] combined.Four risk groups identified as below: | |||
# group 1: No adverse factor | # group 1: No adverse factor | ||
Line 16: | Line 18: | ||
! style="background: #4479BA;; color:#FFF;" | Group | ! style="background: #4479BA;; color:#FFF;" | Group | ||
! style="background: #4479BA;; color:#FFF;" | Altered factors count | ! style="background: #4479BA;; color:#FFF;" | Altered factors count | ||
!5 year prognosis | ! style="background: #4479BA;; color:#FFF;" |5 year prognosis | ||
|- | |- | ||
| style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 1 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | N.O. | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | N.O. | ||
|81000 out of 100000 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 81000 out of 100000 | ||
|- | |- | ||
| style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 2 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | 1 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 1 | ||
|64000 out of 100000 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 64000 out of 100000 | ||
|- | |- | ||
| style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 3 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 3 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | 2 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 2 | ||
|34000 out of 100000 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 34000 out of 100000 | ||
|- | |- | ||
| style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 4 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 4 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | 3/More | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 3/More | ||
|7000 out of 100000 | | style="text-align: center; padding: 5px 5px; background: #F5F5F5;" | 7000 out of 100000 | ||
|} | |} | ||
* Another parallel mechanism for extranodal NK/T cell lymphoma is based on [[tumor]] [[Biology|biologic]] and micro-environmental factors. High Ki-67 [[nuclear]] antigen is a marker for actively proliferation tumor cell which could be a related factor with mass bulk. | |||
==References== | ==References== | ||
Line 47: | Line 50: | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Immunology]] | [[Category:Immunology]] | ||
<references /> |
Latest revision as of 14:00, 2 October 2019
Extranodal NK-T-cell lymphoma Microchapters |
Differentiating Extranodal NK-T-cell lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Extranodal NK-T-cell lymphoma staging On the Web |
American Roentgen Ray Society Images of Extranodal NK-T-cell lymphoma staging |
Risk calculators and risk factors for Extranodal NK-T-cell lymphoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
Extranodal NK/T cell lymphoma survival rate is not well predicted by Ann Arbor staging system. A new system was introduced based on B symptoms, Ann Arbor system, LDH level, and regional lymphadenopathy combined. Another parallel mechanism for extranodal NK/T cell lymphoma is based on tumor biologic and micro-environmental factors. High Ki-67 nuclear antigen is a marker for actively proliferation tumor cell which could be a related factor with mass bulk.
Staging
- Extranodal NK/T cell lymphoma survival rate is not well predicted by Ann Arbor staging system[1]|[2].
- A new system was introduced by a Korean study based on B symptoms, Ann Arbor system, LDH level, and regional lymphadenopathy combined.Four risk groups identified as below:
- group 1: No adverse factor
- group 2: One factor
- group 3: Two factors
- group 4: Three or more factors
Group | Altered factors count | 5 year prognosis |
---|---|---|
1 | N.O. | 81000 out of 100000 |
2 | 1 | 64000 out of 100000 |
3 | 2 | 34000 out of 100000 |
4 | 3/More | 7000 out of 100000 |
- Another parallel mechanism for extranodal NK/T cell lymphoma is based on tumor biologic and micro-environmental factors. High Ki-67 nuclear antigen is a marker for actively proliferation tumor cell which could be a related factor with mass bulk.
References
- ↑ Jaffe ES, Krenacs L, Raffeld M (2003). "Classification of cytotoxic T-cell and natural killer cell lymphomas". Semin Hematol. 40 (3): 175–84. PMID 12876666.
- ↑ Feller AC (2003). "[Classification and differential diagnosis of NK/T-cell lymphomas]". Verh Dtsch Ges Pathol. 87: 43–52. PMID 16888893.